RODERICKUS WILLIAMS: Open Payments
NPI 1679965610 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,186 in 59 payments from 9 companies in 2025. Trend: 2023 $819 · 2024 $1,146 · 2025 $1,186
Food & beverage: $1,186
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 20 | $280 |
| ABBVIE INC. | 12 | $228 |
| Alkermes, Inc. | 6 | $222 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $108 |
| Teva Pharmaceuticals USA, Inc. | 5 | $101 |
| E.R. Squibb & Sons, L.L.C. | 4 | $80 |
| Janssen Pharmaceuticals, Inc | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| LivaNova USA, Inc. | 1 | $44 |
Products named: INGREZZA, VRAYLAR, LYBALVI, CAPLYTA, AUSTEDO XR, ARISTADA, COBENFY, INVEGA SUSTENNA.
Industry payments across LA — which companies pay providers there.
